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Summary
The potential for development of biomedical technologies
capable of extending the human lifespan raises at least two
kinds of question that it is important both to distinguish and
to connect with one another: scientific, factual questions re-
garding the feasibility of life extension interventions; and
questions concerning the ethical issues related to the exten-
sion of life- and healthspans. This paper provides an ac-
count of some life extension interventions considered to be
amongst the most promising, and presents the ethical ques-
tions raised by the prospect of their pursuit. It is suggested
that problems concerning the effects of these technologies
on health care resources and on intergenerational relation-
ships will be the most difficult to tackle.
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Introduction: human longevity and
lifespan extension
The average human lifespan has dramatically increased in
the course of human history [1]. A comparison between
early estimates of human longevity and data on wealthy
countries today shows that life expectancy at birth has
nearly tripled. Much of this increase took place in the past
150 years, after the industrial era, and was due to advances
in nutrition, sanitation and medicine which brought about a
significant reduction in juvenile mortality. This phenomen-
on is commonly known as the “epidemiological transition”
[2]: increasingly, acute infectious diseases declined and
mortality risks shifted to older ages, in conjunction with the
rise of chronic degenerative diseases.
During the second half of the 20th century a crucial turning
point has been reached in the increase of human life ex-
pectancy in industrialised countries: “from an earlier era
dominated by the decline of acute infectious disease among
juveniles, to a more recent era involving the decline of
chronic degenerative disease among the elderly” [1]. Since
1970 or thereabouts a more rapid decline in death rates at
higher ages is taking place: life expectancy is now driven
by the extension of life at more advanced ages [3]. Data
collected within national populations show that among the
most significant factors affecting this trend is the reduction
of mortality rates due to cardiovascular disease and cancer
[1].
Biodemographic and epidemiological studies indicate that
a significant proportion of the decline in death rates among
the elderly in recent decades might be ascribed to medical
progress [4]. It is likely that achievements in medical in-
terventions on several age-related ailments, as well as the
development of geriatric medicine, directed towards both
prevention and treatment, have contributed to this trend.
However, this hypothesis is not enough to form reliable
predictions on future trends in average life extension.
Hitherto the available demographic and epidemiological
evidence can only suggest that the hypothesis of a further
reduction in mortality at more advanced ages due to med-
ical progress is highly plausible, yet this prospect is not
ineluctable. The increase in life expectancy and the con-
stant decline in death rates among the elderly in developed
countries results from a complex interplay of environment-
al, genetic and medical factors [4], and predictions of future
trends in average lifespan should be treated with caution.
We should not forget that these forecasts are used to de-
termine governmental policies on future health care and
other social needs, and could inform public decisions on
the financing of pensions and of programmes to support the
elderly population [5, 6].
When discussing projections on future trends in life expect-
ancy, researchers in the field of the biology, demography
and epidemiology of human aging and longevity disagree
on how long a future increase in the human lifespan might
be. A survey of over 60 demographers, gerontologists and
aging researchers asked to estimate life expectancy for a
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person born in 2100 shows that opinions differ widely, with
a half of forecasts not exceeding 100 years and a minority
of the most optimistic predictions ranging from 500 to 5000
years [7]. These hazardous estimates are not surprising if
one considers that interviewees who suggested them are re-
searchers in the field of life extension. They include Mi-
chael Fossel, a researcher in the field of telomerase activa-
tion as a treatment for cellular senescence and an advocate
of strategies to reverse the aging process; Roy Walford,
a pioneer in the field of caloric restriction as a means to ex-
tend the human lifespan and a member of the crew of the
Biosphere 2 project; and biogerontologist Aubrey de Grey,
one of the most vigourous proponents of life extension re-
search and editor in chief of the journal Rejuvenation Re-
search, who argued that a newborn in the year 2100 would
live 5000 years.
Aging as a target for biomedical
intervention
This survey corroborates the lack of consensus among sci-
entists about whether research on age-related diseases and
on the mechanisms of senescence might lead to the exten-
sion of the human lifespan [8]. On the one hand, optimist-
ic proponents of life-extension claim that there are “broken
limits” to life expectancy, and that existing knowledge of
human aging provides a basis for the manipulation of the
aging process itself, which will eventually enhance human
longevity [9]. On the other hand, more cautious scientists
believe that there are insurmountable “biological limits” to
the human lifespan, and that aging is a complex and mul-
tifaceted process which cannot be easily manipulated and
controlled [10].
Life extension research is part of a larger biomedical field
commonly known as anti-aging medicine. Emerging in the
1990s as a pioneering speciality in medical practice, anti-
aging medicine has gained increasing consideration in the
scientific as well in the public discourse [11]. The goal of
anti-aging medicine is to prolong both a healthy lifespan
and life expectancy by means of a combination of various
techniques, such as advanced biomedical interventions, di-
etary regimes, physical training and aesthetic procedures
[12]. A recent study of the Swiss National Centre for Tech-
nology Assessment (TA-SWISS) provides a comprehens-
ive review of the vast array of interventions covered by
anti-aging medicine [13].
Proponents of anti-aging medicine have made a number
of predictions as to how far life- and healthspans would
be extended through a multi-modal medical approach [11].
These predictions, as we have seen, are varied, and one of
the reasons for this variation is the difference in opinions
as to whether or not anti-aging medicine can be expected
to delay the onset of the aging process, or to arrest or
even reverse it, thus restoring vitality and function to the
aging organism [14]. In addition, all anti-aging scientists
agree that aging is a target for biomedical intervention [11].
Indeed, the basic assumption underlying life extension re-
search is that biological aging, or “senescence”, is a patho-
logical phenomenon that can be prevented or reversed [15].
This assumption has been partially fuelled by progress in
research on the biological mechanisms of senescence and
by the florescence of new theories of ageing, which have
definitively abandoned the naïve idea of the existence of a
“biological clock” that measures the length of human life
and activates a destructive process. These more complex
views on the mechanisms of senescence – such as the hy-
pothesis that aging results from the accumulation of unre-
paired damage in cells, tissues and organs [16, 17] – are
much more consistent with the hypothesis that an extension
of the human lifespan could be achieved through medical
intervention, thus overcoming the present limits to human
longevity [18].
This view is explicitly opposed to much of the work that
has been done in the field of gerontology to overcome the
pathological model of old age developed by the medical
profession in the 19th century [19]. This disease-oriented
approach to aging was progressively abandoned during the
20th century: aging was gradually distinguished from dis-
ease, and the complex relationship between aging and dis-
ease began to be untangled. Nowadays, several attempts
have been made in gerontology to define the general char-
acteristics of aging, aiming to separate aging from other
time-related processes and to clear the relationship between
aging and age-related diseases. According to this view, age-
related diseases should be distinguished from the aging
process, which is not a disease as such, and should not be
considered as a pathological phenomenon liable to manipu-
lation [20, 21]. As the anthropologist Courtney E. Mykytyn
points out, “anti-aging proponents seek to nullify this rhet-
oric by speaking instead of aging as the underlying factor
so that osteoporosis and the like become a symptom of
aging itself” [11].
Anti-aging medicine aims to promote research on biomed-
ical technologies that have the potential to counteract or
halt the degenerative process we habitually call “normal”
or “natural” human aging [12]. Their way of thinking is
supported by the bioethicist Arthur L. Caplan, who claims
that the very same “naturalness” of aging, i.e., the idea
that aging is part of human nature, is at issue [22]. Caplan
grounds his argument on the evolutionary theory of aging,
according to which senescence is simply a by-product of
selective forces and has no particular function [23, 24]. If
aging is not a “natural”, intrinsic component of evolution, it
may be manipulated exactly like any other process deemed
as unnatural or pathological [22].
The proliferation of anti-aging practitioners and the in-
creasing relevance attributed to life extension research in
mainstream journals and books is partly due to the piloting
force of the American Academy of Anti-Aging Medicine
(A4M), whose primary goal is to have anti-aging medicine
acknowledged as a medical speciality and a field of sci-
entific research [11]. Founded in 1992, the A4M numbers
22 000-plus members representing over 105 nations (ht-
tp://www.worldhealth.net). The vast majority of them are
not gerontologists or geriatricians but rather medical doc-
tors from different specialities such as cardiology, endo-
crinology, rehabilitation, and sports medicine, not to men-
tion nutritionists, chiropractors and even psychotherapists
[11]. The Academy supports national and international
conferences, accredits anti-aging practitioners, seeks to at-
tract funding for research in life extension strategies and
Review article Swiss Med Wkly. 2011;141:w13181
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 2 of 6
lobbies against mainstream gerontology, which accuses
anti-aging proponents of being “snake oilers” [11].
The strategy adopted by anti-aging advocates is to put for-
ward optimistic predictions on the feasibility and effective-
ness of a range of interventions to prolong healthy lifespan
and extend human longevity. A brief overview of some life
extension interventions, in particular those that are deemed
to be amongst the most promising, may help to clarify their
feasibility and provide a basis for further discussion on the
ethical implications of life extension as a biomedical goal.
Lifespan extension strategies:
foreseeable interventions?
A significant lengthening of lifespan in a variety of species
(e.g., yeast, worms, fish, rats and mice) can be induced by
caloric restriction [25]. The caloric restriction protocol dif-
fers from starvation in that it consists of a lower caloric
intake (by 30–70%) associated with wholly adequate
amounts of proteins, vitamins and minerals, fatty acids and
other nutrients. Basically this experimental intervention in-
creases longevity patterns through the extension of healthy
lifespan and the delay in the onset of senescence [26]. To
understand whether caloric restriction may have the same
beneficial impact on human aging, and how long it should
last to produce beneficial effects on humans, studies on the
effects of a 30% dietary restriction in rhesus monkeys were
initiated. Preliminary results demonstrated that caloric re-
striction may slow or reduce some age-related physiolo-
gical changes [27–30]. Findings of a 20-year longitudin-
al study in rhesus monkeys have recently been published,
showing that moderate caloric restriction reduces the incid-
ence of aging-related deaths and delays the onset of age-
related pathologies such as diabetes, cancer, cardiovascu-
lar disease, and brain atrophy [31]. A few observational
studies suggest that caloric restriction has beneficial ef-
fects on human health and aging [32]. These include natur-
al experiments such as that conducted by a Spanish nurs-
ing home where patients who underwent a 35% reduction
in caloric intake over 3 years reported fewer visits to the
infirmary and a slight decrease in death rate [33]. Data
from a pilot caloric restriction experiment using human
subjects (e.g., the Biosphere 2 project) also suggest that
the caloric restriction regimen improves several physiolo-
gical functions in humans [34]. More recently, a review of
information gathered in research on caloric restriction in
humans shows that risk factors for cardiovascular diseases
and diabetes are reduced in people on long-term caloric re-
striction [35]. These observations are highly encouraging
and strongly suggest that caloric restriction may increase
longevity and is likely to improve general health and well-
being in aged humans. However, some studies have invest-
igated the quality of life and potential “pitfalls” of long-
term caloric restriction in humans [36, 37]. Although not
clearly addressed in the literature, potential negative side
effects may include hypotension, infertility, bone thinning
and osteoporosis, and psychological conditions such as de-
pression and irritability. Thus, the caloric restriction re-
gimen used experimentally may not be feasible for most
humans. It has been suggested that the development of
interventions mimicking the effect of caloric restriction
might provide the same health benefits and slowing of
the aging process as a rigorous caloric restriction regimen,
while avoiding the need to reduce food and caloric intake
[37–39].
Besides caloric restriction, several hormone supply or re-
placement strategies are deemed to contrast the functional
decline associated with aging [40]. Hormone treatments
may include growth hormone (GH), dehydroepiandroster-
one (DHEA), melatonin, testosterone, progesterone and
oestrogen. Amongst these, the “anti-aging” action of GH
has been widely extolled. In 1990 a noted study reported
the effect on body composition of administering human GH
for six months to 12 older men [41]. This study unleashed
a spate of publications extolling the benefits of growth hor-
mone in reversing or preventing aging [42]. Beyond these
claims for GH’s miraculous effects, research on GH con-
tinues to be promising. Release of GH from the pituitary
gland declines with age and reduced levels of GH almost
certainly contribute to age-related loss of muscle mass, in-
crease in adiposity and loss of bone mineral [41, 43]. These
changes resemble those observed in adult GH deficiency
and may be reduced or reversed by GH therapy. However,
there is no evidence for effects of GH therapy on life ex-
pectancy. It was claimed that, although GH supplement-
ation has been shown to improve some of the physiolo-
gical changes associated with aging, GH therapy did not
prove to be life extending [44]. Indeed, it was suggested
that the “anti-aging” action of GH refers to its effects on
body composition and functioning in elderly individuals
rather than to its role in determining longer lifespan [45,
46]. Still, further uncertainty remains concerning the goals
of foreseeable treatments based on GH [47]. Indeed, it is
questionable whether they should include preserving abil-
ity to work, preserving independence, avoiding need for
care, boosting vitality, or simply reducing morbidity. Fin-
ally, scientific knowledge of the possible individual risks or
unwanted effects for GH-treated patients is still scant and
warrants further research. In fact, it is not known whether
long-term administration of growth hormone in the elderly
is potentially harmful, particularly with regard to the risk of
cancer [42, 47].
Research on interventions aimed at prolonging healthy
lifespan and delaying the aging process includes reduction
of oxidative damage and telome-rase activation. Recent
studies have demonstrated that oxidative stress is a major
determinant of lifespan in worms and flies, and that it can
be counteracted by pharmacological intervention or genetic
engineering techniques [48–52]. These studies have proved
that strategies designed to counteract oxidative damage
postpone the onset of senescence in invertebrate model or-
ganisms and significantly extend their lifespan. However,
these strategies did not induce a similar extension of the
lifespan in mammals, where a more complex control sys-
tem working via the aging process probably needs more
specific and elaborate interventions [26]. As reviewed by
Harman, more sophisticated measures to reduce oxidative
damage may include, among others, caloric restriction, an-
tioxidant enzymes, superoxide dismutase (SOD) mimics,
and dietary antioxidants [53]. At present, however, there is
still scant evidence from human studies that interventions
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aimed at reducing oxidative stress damage might lead to a
reduction in the rate of aging.
There is growing evidence that telomere shortening limits
the regenerative potential of organ cells during aging and
chronic disease [52]. Telomeres are stretches of noncoding
DNA located at the ends of each linear chromosome, which
play an important role in cellular senescence due to cell
replication. Each cell division results in ever-shorter telo-
meres and altered telomere structure. It was observed that
activation of the telomerase enzyme regenerates telomeres,
prevents replicative senescence and immortalises human
primary cell cultures [54, 55]. The requirement of te-
lomerase for human cell immortality, together with the ob-
servation that telomeres shorten with age, led to the hy-
pothesis that telomere length may regulate cell replicative
lifespan in vivo and eventually contribute to aging. The
possibility of using telomerase activation to extend the re-
generative potential of cells during aging and chronic dis-
ease depends on the effects of telomerase activity on tu-
mour formation [52, 56]. Indeed, studies from telomerase-
deficient mice suggest a dual role of telomere shortening
and telomerase activation during cancer initiation and pro-
gression.
Life extension as a morally
questionable biomedical goal
None of the potential life extension interventions reviewed
in the previous paragraph seems to provide conclusive
evidence for future applications in humans. Although anti-
aging predictions are much less reliable than their propon-
ents claim, they have a tremendous impact on our under-
standing of aging and of the scope of biomedical research
[11, 57]. Predictions of the feasibility and effectiveness of
life extension interventions are tied to the belief that sen-
escence should be considered a painful pathological phe-
nomenon that has to be treated. Such predictions main-
tain that the surge in population aging might contribute to
socioeconomic stagnation or regression, and represents a
collective and individual risk that should be counteracted
through public health policies aimed at promoting anti-
aging interventions [57]. In fact, life extension advocates
picture aging as a “global dilemma” and anti-aging medi-
cine as the sole viable solution to the mounting public ex-
penditure on the elderly populations in developed countries
[12]. Hence it is not surprising that the voluminous A4M
website is named “worldhealth.net”.
Although overoptimistic and hazardous, these predictions
contribute to the construction of life extension as a biomed-
ical goal, moored to a moral obligation to halt the aging
process for the sake of the global population [11]. The pur-
suit of this goal promises to bring previously unimagin-
able benefits to mankind, but generates significant worries
as well. Of all the arguments that have been put forward
against these scientific developments, concerns about dis-
tributive justice offer the best prospects for a critical stance
on anti-aging medicine and research. Even if life exten-
sion interventions should reduce the health care needs of
the elderly population, problems may nonetheless arise for
other basic resources, such as water or food. In fact it can
be predicted that one of the consequences of an increase in
the lifespan would be the increase in the population; if this
is so, it seems likely that the scientific success of life-ex-
tending technologies would impose an unbearable burden
on the environment and its resources.
In any case, even if population is equal, the unbalance
between the young and old may pose problems of intergen-
erational justice [58]. The most evident is tied to pensions:
the more the ratio between the generations favours the
older ones, the more the younger will need to contribute
to guarantee the social security of the former. Of course,
the younger will eventually be repaid for their sacrifices
by a longer life, and the increase in the lifespan should
also determine a prolongation of active and working life for
the elderly; however, prolonging the working life of people
with increased lifespans may not be beneficial for them,
and may itself pose further problems of justice. Large num-
bers of still working, much older people might create ser-
ious problems for the new generations striving for success
or acknowledgment of their capacities.
Another ethical worry is that, in all probability, life-ex-
tending technologies would be implemented for a relatively
long time only in the more affluent countries that already
have a high life expectancy; this would further widen the
gap between resources and opportunities among sections of
the world population [59]. Some object to this considera-
tion, noting that all scientific developments have first been
implemented in some small areas of the world and have
achieved widespread dissemination only with time; life ex-
tension techniques would simply follow along the same
path [60]. A possible rejoinder is that, unlike other cases,
what is at issue is a qualitatively altogether new benefit, to
be conferred on some, while a large part of the world pop-
ulation still lacks the resources even to attain the condition
that would be “cured” by the new technologies. It is not that
we have found a therapy for some disease that previously
went uncured, but that we have decided to cure something
that previously was not considered a disease; and it could
be argued that, as a matter of international justice, uncon-
troversial diseases with lost standing should take preceden-
ce, in the health care agenda, over new and controversial
objects of care.
It can also be argued that the prospect of increasing the
lifespan of only a part of humankind is morally objection-
able because it would create a sort of new, “posthuman”
or “more-than-human” race, living alongside the unmodi-
fied one. To this it has been answered that such a situation
would not be so new and morally objectionable, since it
is simply inevitable: it is a fact that, nowadays, there are
dramatic differences in the life expectancy of people from
different countries, and in fact we could say that parallel
populations with very different life opportunities already
inhabit our earth [61]. While unpleasant this fact is not un-
just, because the fact that we cannot confer a benefit on
everyone does not justify or mandate that we confer it on
no one, but only that we try to extend it to everyone in due
course. As a matter of fact, it is only the spread of certain
technologies in the richest areas of the world that may lead
to their benefits being extended to the less fortunate areas.
Moreover, the advantages conferred by life extension tech-
niques are not positional, that is, they are not inherently de-
pendent on the fact that others are not enjoying them; there-
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fore, fairness cannot dictate that we stop seeking them for
ourselves, but only that we work to eventually attain uni-
versal provision.
A possible rejoinder is that past injustices do not justify
new ones; it is true that analogous inequities have been jus-
tified in the past, since they were not considered relevant
moral failings. However, it must be borne in mind that in
those days the world was in no way thought of as a glob-
al community, and the injustice of differences in life cir-
cumstances among different regions could easily be under-
rated. The situation is far different today, when we have a
much clearer consciousness of the globalised world’s inter-
dependency, and a similar attitude may in fact not be justi-
fied [62].
Conclusions
Optimistic predictions of the feasibility and effectiveness
of life extension should be critically reviewed in the light
of their ethical and social implications. Some anti-aging
scientists claim that arguments against anti-aging medicine
will simply be dismissed by research outcomes [63]. We
would claim that the problem is not with the availability of
results, but with defining the nature of what we consider
“results”.
The idea that life extension research will necessarily trans-
late into what some judges interpret as a result (i.e. the cure
of aging) is problematic, because the translational process
from potential life extension interventions into reality is not
only a matter of science. Suppose we have laboratory ad-
vances that are promising for the future translation of labor-
atory work to the clinic. This result would matter scientific-
ally, but would not solve the ethical and social questions
of life-extending interventions. Even if we should succeed
in the laboratory, the problems of equitable access to such
interventions, the impacts of the future implementation of
life extension on health care systems, the risk of pressure to
make use of life extension techniques – all these issues will
still be with us. Here, more than ever, it must be stressed
that the “nature” of what we consider “results” matters not
only scientifically, but also ethically and socially [64]. Eth-
ical and social debate on these issues is therefore much
needed, along with scientific research and discussion.
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